Clinical Evidence: What the Trials Actually Show
Mounjaro vs Wegovy Doses: Understanding the Key Differences
When comparing Mounjaro vs Wegovy doses, the fundamental difference lies in their dosing schedules and mechanisms. Wegovy follows a 5-step dose escalation over 16 weeks: starting at 0.25mg for weeks 1-4, progressing through 0.5mg, 1mg, 1.7mg, and reaching the maintenance dose of 2.4mg by week 17. Mounjaro uses a 4-step progression with different dose strengths: 2.5mg, 5mg, 10mg, and 15mg maximum. This reflects their different active ingredients – Wegovy contains semaglutide (a GLP-1 receptor agonist), while Mounjaro contains tirzepatide (a dual GIP and GLP-1 receptor agonist).
The dosing frequency remains consistent for both treatments – once-weekly injections using pre-filled pens. However, the escalation timeframes differ, with Wegovy requiring a longer titration period to reach therapeutic doses. Both are prescription-only medicines requiring clinical assessment and ongoing monitoring. Understanding these Mounjaro vs Wegovy doses helps patients and prescribers choose the most appropriate treatment pathway for individual weight management goals.
UK Weight Loss Results: Pricing and Clinical Access
At EverydayMeds, Wegovy pricing reflects the dose escalation schedule, starting with our 0.25mg starter dose at £79.99 (with new customer code FIRST40). The full dose progression includes 0.5mg at £94.99, 1mg at £99.99, 1.7mg at £139.99, and maintenance 2.4mg at £209.99. Our Getting Started bundles streamline the initial months – the Intro Trio (0.25mg, 0.5mg, 1mg) costs £299.99, while the Progress Trio (0.5mg, 1mg, 1.7mg) is £369.99. Returning customers benefit from code DOSE25 applied at checkout.
For maintenance therapy, our Ultimate Stability Trio provides three months of 2.4mg supply for £649.99, ensuring consistent treatment without multiple orders. The convenience factor extends beyond pricing – our 2-pen and 3-pen bundles reliable supply continuity during the critical dose escalation phase. All bundles include next-day cold-chain delivery once prescribed, maintaining the temperature-controlled storage requirements essential for both Mounjaro and Wegovy effectiveness.
STEP Trial Evidence: What Clinical Data Shows for Wegovy
The landmark STEP clinical trials provide robust evidence for Wegovy's effectiveness in weight management. STEP 1 demonstrated approximately 15% average weight loss at 68 weeks compared to 2.4% with placebo, while STEP 3 showed around clinically studied weight loss when combined with intensive behavioural therapy. These results formed the basis for MHRA approval and NICE recommendation TA875.
STEP 5's long-term data revealed sustained weight loss of approximately 15.2% at 2 years, addressing questions about durability. The SELECT cardiovascular outcomes trial showed a 20% reduction in major adverse cardiovascular events (HR 0.80), published in leading medical journals including Wilding et al., NEJM, 2021. When comparing Mounjaro vs Wegovy doses and results, it's important to note that different trial designs, populations, and endpoints make direct percentage comparisons inappropriate.
How Wegovy's GLP-1 Mechanism Supports Weight Management
Wegovy works as a GLP-1 receptor agonist, mimicking the action of naturally occurring incretin hormones that regulate appetite and food intake. The medication binds to GLP-1 receptors in the brain's appetite control centres, reducing hunger signals and promoting satiety after smaller meals. This mechanism helps patients feel fuller for longer periods, naturally reducing caloric intake without the constant struggle against appetite. The dose escalation from 0.25mg to 2.4mg allows the body to adapt gradually, minimising side effects while building therapeutic effectiveness. Unlike restrictive dieting approaches, Wegovy works with the body's natural fullness mechanisms to support sustainable weight management alongside lifestyle modifications.
Streamlined Ordering Process: Assessment to Delivery
EverydayMeds has simplified access to both treatments through our comprehensive online service. The process begins with a 3-minute clinical assessment covering medical history, current medications, weight management goals, and contraindications. Our UK prescribers review each application within 3 working days (or 24 hours with express service), ensuring clinical appropriateness for either Mounjaro or Wegovy doses. Once approved, medications are dispatched via next-day delivery using temperature-controlled cold-chain logistics. Our GPhC-registered pharmacy (#9012878) maintains strict storage protocols throughout the supply chain, from receipt to your door. The entire process, from assessment to first injection, typically takes 4-5 working days, removing traditional barriers to prescription weight management support.
Storage and Practical Considerations for Both Treatments
Storage requirements highlight a key practical difference when comparing Mounjaro vs Wegovy doses and convenience factors. Both medications require refrigeration at 2-8°C before first use, but Wegovy offers superior travel flexibility with 6 weeks of room temperature storage (below 30°C) once removed from the fridge. Mounjaro provides only 21 days at room temperature, making Wegovy more suitable for extended travel or irregular storage situations. Both use pre-filled injection pens – Wegovy's FlexTouch technology and Mounjaro's KwikPen – designed for easy self-administration. The dose escalation schedules require different pen strengths over time, making our bundle options particularly valuable for ensuring smooth transitions. Each pen contains 4 doses, administered once weekly, with clear dose counters to track remaining medication.
UK Clinical Evidence: Real-World Weight Loss Outcomes
Beyond clinical trials, real-world evidence from UK weight management services supports the effectiveness of both treatments when prescribed appropriately. NHS specialist weight management services report positive outcomes with both Mounjaro and Wegovy doses, though individual responses vary significantly. The key to success lies in comprehensive support including dietary counselling, physical activity guidance, and ongoing clinical monitoring. Patient registries show that adherence to dose escalation schedules correlates strongly with weight loss outcomes, highlighting the importance of our bundle approach for treatment continuity.
NICE guidance TA875 recommends Wegovy within specialist weight management services, recognising both its clinical efficacy and cost-effectiveness for appropriate patients. The guidance emphasises that weight management medications work best as part of comprehensive lifestyle interventions, not as standalone treatments. This aligns with EverydayMeds' approach of supporting patients throughout their weight management journey with ongoing clinical oversight and practical support for medication management.
Making Your Choice: Clinical Assessment and Next Steps
Both Wegovy and Mounjaro are available from EverydayMeds, and your prescriber can help determine which dosing approach best suits your individual circumstances. Factors influencing the choice include your medical history, previous weight management attempts, lifestyle considerations like travel requirements, and personal preferences for dose escalation schedules. Our clinical team, operating under GPhC registration #9012878, provides ongoing support throughout treatment, monitoring effectiveness and managing any side effects that may occur. The 3-minute online assessment covers all relevant factors, ensuring you receive the most appropriate prescription-only medicine for your weight management goals. Start your clinical assessment today using code FIRST40 for new customers, and take the first step towards evidence-based weight management support with next-day delivery to your door. Begin your Wegovy assessment here and join thousands of UK patients who have chosen EverydayMeds for their weight management journey.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
